AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects

AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects

Abstract Imatinib resistance remains an unresolved problem in CML disease. Activation of JAK2/STAT3 pathway and increased expression of RUNX1 have become one reason for development of imatinib resistance in CML subjects. Metformin has gained attention as an antileukemic drug in recent times. However...

Full description

Bibliographic Details
Main Authors: Meher Bolisetti Gayatri, Rama Krishna Kancha, Abhayananda Behera, Dorababu Patchva, Nagaraj Velugonda, Sadasivudu Gundeti, Aramati Bindu Madhava Reddy
Format: Article
Language:English
Published: Nature Publishing Group 2023-10-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-023-01700-x

Similar Items

Similar Items